🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Camrelizumab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  2. Camrelizumab

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 small molecule active

    1 trial

  3. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Neoplasms

    phase 2 small molecule active

    1 trial

  4. Camrelizumab with vinorelbine and cisplatin

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  5. Cangpo Liujun Prescription

    The First People's Hospital of Lianyungang

    Cancer-Related Fatigue

    phase 2 small molecule active

    1 trial

  6. Cannabidiol Capsules, Füllstoffmischung DAC in hardshell gelatine capsules, size 1, is used as placebo. Füllstoffmischung DAC consists of mannitol 99.5 % and silloidal silicon dioxide (Aerosil®) 0.5 %.

    The George Institute

    Remitted early phase schizophrenia

    phase 2 small molecule active

    1 trial

  7. Cannabidiol Placebo Capsules, Cannabidiol Capsules

    The George Institute

    Alcohol dependence

    phase 2 small molecule active

    1 trial

  8. Capecitabina KERN PHARMA 150 mg comprimidos recubiertos con película EFG, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Irinotecán Hospira 20 mg/mL concentrado para solución para perfusión EFG., Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Capecitabina

    The George Institute

    Localised Colon Cancer (stage II-III)

    phase 2 small molecule active

    1 trial

  9. Capecitabine

    Vera Therapeutics

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  10. Capecitabine

    The First People's Hospital of Lianyungang

    Biliary Carcinoma

    phase 2 small molecule active

    1 trial

  11. Capecitabine

    The University of Hong Kong

    Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  12. Capecitabine-Oxaliplatin-Irinotecan Combination

    The First People's Hospital of Lianyungang

    Unresectable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  13. Carboplatin

    United Therapeutics Europe Ltd

    Hormone Refractory Prostate Cancer

    phase 2 small molecule active

    1 trial

  14. Carboplatin

    United Therapeutics Europe Ltd

    Recurrent Fallopian Tube Carcinoma

    phase 2 small molecule active

    1 trial

  15. Carboplatin

    Atrium Therapeutics

    Lung Cancer Stage II

    phase 2 small molecule active

    1 trial

  16. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Avastin 25 mg/ml concentrate for solution for infusion., Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion.

    TESARO Bio Netherlands B.V.

    Ovarian Neoplasms

    phase 2 small molecule active

    1 trial

  17. Carboplatin plus Paclitaxel

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  18. CardiolRx

    Cardiol Therapeutics

    Acute Myocarditis

    phase 2 small molecule active

    1 trial

  19. CardiolRx

    Cardiol Therapeutics

    Acute Myocarditis

    phase 2 small molecule completed

    1 trial

  20. Carvedilol

    NORTHWEST BIOTHERAPEUTICS INC

    Post-Traumatic Stress Disorder

    phase 2 small molecule active

    1 trial

  21. Cediranib

    United Therapeutics Europe Ltd

    Alveolar Soft-part Sarcoma

    phase 2 small molecule active

    1 trial

  22. Celecoxib

    United Therapeutics Europe Ltd

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  23. Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.

    Lxo Ireland Designated Activity Company

    Liver Transplant Rejection

    phase 2 other completed

    1 trial

  24. Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a phase I trial

    Pari Pharma GmbH

    Inclusion Body Myositis

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources